(19)Therefore, the registration provisions should require manufacturers and importers to generate data on the substances they manufacture or import, to use these data to assess the risks related to these substances and to develop and recommend appropriate risk management measures. To ensure that they actually meet these obligations, as well as for transparency reasons, registration should require them to submit a dossier containing all this information to the Agency. Registered substances should be allowed to circulate on the internal market.
◷
New version applies from 20/01/2009 — introduced by CLP Regulation.
111 provisions change.
Later versions: 20/02/2009, 27/06/2009, 02/04/2010, 01/12/2010, 21/02/2011, 06/03/2011, 05/05/2011, 10/12/2011, 01/06/2012, 05/06/2012, 09/10/2012, 06/03/2013, 21/04/2013, 01/07/2013, 10/04/2014, 22/08/2014, 01/01/2015, 23/03/2015, 13/05/2015, 01/06/2015, 25/09/2015, 27/12/2015, 03/02/2016, 08/03/2016, 01/04/2016, 21/06/2016, 14/07/2016, 11/10/2016, 02/01/2017, 02/03/2017, 04/07/2017, 10/10/2017, 31/01/2018, 01/03/2018, 09/05/2018, 01/12/2018, 07/01/2019, 02/07/2019, 30/10/2019, 01/01/2020, 27/02/2020, 28/04/2020, 24/08/2020, 01/01/2021, 15/02/2021, 05/07/2021, 25/08/2021, 01/10/2021, 08/01/2022, 01/03/2022, 01/05/2022, 14/10/2022, 17/12/2022, 28/05/2023, 29/06/2023, 06/08/2023, 01/12/2023, 06/06/2024, 10/10/2024, 22/04/2025, 23/06/2025, 01/09/2025, 23/10/2025, 11/05/2026, 22/06/2026.
Recital 19 changes in this version: compare with the current text.